尼古丁胺:在玻璃眼治疗中具有很强的潜力
Silvia Babighian1, Irene Gattazzo1, Maria Sole Zanella1
1Department of Ophthalmology, Ospedale Sant'Antonio, Azienda Ospedaliera, 35127 Padova, Italy.
Biomedicines
|August 29, 2024
概括
尼古丁胺通过保护视神经,并可能降低眼内压力 (IOP) 显示出对玻璃眼治疗的希望. 需要进一步的研究来证实它在患者中的有效性和安全性.
科学领域:
- 眼科医生 眼科 眼科
- 神经科学是一个神经科学.
- 营养科学 营养科学
背景情况:
- 由于治疗方法有限和副作用有限,眼会带来重大管理挑战.
- 尼古丁胺是一种营养物质,可为玻璃眼瘤提供潜在的神经保护和眼内压力 (IOP) 调节.
研究的目的:
- 审查当前关于尼古丁胺胺用于绿眼管理的文献.
- 分析尼古丁胺的机制,疗效和安全性在玻璃眼.
主要方法:
- 系统的PubMed搜索尼古丁胺在眼睛高血压和玻璃眼病中的治疗作用.
- 包括评估对视网膜质细胞 (RGC),视神经,IOP和神经炎症的影响的研究.
主要成果:
- 临床前证据表明,尼古丁胺保护RGC和视神经完整性.
- 尼古丁胺可以通过眼球血流和水性幽默动态减少与玻璃眼相关的神经炎症,并调节IOP.
结论:
- 尼古丁胺是一种有前途的治疗方法,可用于治疗青光眼,提供神经保护和IOP降低.
- 建议进行进一步的研究,以确定青光眼患者的疗效,安全剂量和长期安全性.
相关概念视频
Open Angle Glaucoma: Treatment
408
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
408
Angle Closure Glaucoma: Treatment
454
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
454
Glaucoma: Overview
528
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
528
Drugs Acting on Autonomic Ganglia: Stimulants
1.3K
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
1.3K
Direct-Acting Cholinergic Agonists: Pharmacological Actions
1.2K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
1.2K
Direct-Acting Cholinergic Agonists: Therapeutic Uses
704
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
704


